Actively Recruiting
Open-label Phase 1 Study Evaluating Safety and Early Effects of BA1301 in Adults with Advanced Solid Tumors
Led by Shandong Boan Biotechnology Co., Ltd · Updated on 2026-10-13
70
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and early signs of effectiveness of BA1301 in people with advanced solid tumors. This is an open-label, Phase 1, first-in-human trial focusing on participants whose tumors cannot be surgically removed and who have failed or cannot tolerate standard treatments. The study is sponsored by Shandong Boan Biotechnology Co., Ltd. Participants receive BA1301 intravenously once every three weeks as part of a single treatment group. The trial includes an active treatment phase with BA1301 administration and safety follow-up lasting up to two years after treatment ends to monitor adverse events and serious adverse events. During the study, participants will be monitored for side effects and tolerability through assessments including tumor tissue analysis and evaluation of lesions using standard solid tumor criteria. Researchers will collect data on adverse events from the start of treatment through the follow-up period. The total duration includes treatment cycles every three weeks and safety monitoring for up to two years after treatment completion.
CONDITIONS
Brief Title
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.
Research Team
Z
Zhang Yanqiao
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here